IBDEI0KT ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9859,2)
 ;;=Pemphigoid^91108
 ;;^UTILITY(U,$J,358.3,9860,0)
 ;;=364.10^^44^558^54
 ;;^UTILITY(U,$J,358.3,9860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9860,1,3,0)
 ;;=3^Iridocyclitis, Chronic
 ;;^UTILITY(U,$J,358.3,9860,1,4,0)
 ;;=4^364.10
 ;;^UTILITY(U,$J,358.3,9860,2)
 ;;=Iridocyclitis, Chronic^24398
 ;;^UTILITY(U,$J,358.3,9861,0)
 ;;=054.44^^44^558^55
 ;;^UTILITY(U,$J,358.3,9861,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9861,1,3,0)
 ;;=3^Iridocyclitis, H Simplex
 ;;^UTILITY(U,$J,358.3,9861,1,4,0)
 ;;=4^054.44
 ;;^UTILITY(U,$J,358.3,9861,2)
 ;;=Iridocyclitis, H Simplex^266565
 ;;^UTILITY(U,$J,358.3,9862,0)
 ;;=053.22^^44^558^56
 ;;^UTILITY(U,$J,358.3,9862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9862,1,3,0)
 ;;=3^Iridocyclitis, H Zoster
 ;;^UTILITY(U,$J,358.3,9862,1,4,0)
 ;;=4^053.22
 ;;^UTILITY(U,$J,358.3,9862,2)
 ;;=Iridocyclitis, H Zoster^266554
 ;;^UTILITY(U,$J,358.3,9863,0)
 ;;=364.42^^44^558^111
 ;;^UTILITY(U,$J,358.3,9863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9863,1,3,0)
 ;;=3^Rubeosis Iridis
 ;;^UTILITY(U,$J,358.3,9863,1,4,0)
 ;;=4^364.42
 ;;^UTILITY(U,$J,358.3,9863,2)
 ;;=Rubeosis Iridis^268716
 ;;^UTILITY(U,$J,358.3,9864,0)
 ;;=364.59^^44^558^59
 ;;^UTILITY(U,$J,358.3,9864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9864,1,3,0)
 ;;=3^Iris Atrophy,Other
 ;;^UTILITY(U,$J,358.3,9864,1,4,0)
 ;;=4^364.59
 ;;^UTILITY(U,$J,358.3,9864,2)
 ;;=Iris Atrophy^268731
 ;;^UTILITY(U,$J,358.3,9865,0)
 ;;=224.0^^44^558^11
 ;;^UTILITY(U,$J,358.3,9865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9865,1,3,0)
 ;;=3^Benign Neopl of Iris
 ;;^UTILITY(U,$J,358.3,9865,1,4,0)
 ;;=4^224.0
 ;;^UTILITY(U,$J,358.3,9865,2)
 ;;=^267670
 ;;^UTILITY(U,$J,358.3,9866,0)
 ;;=364.72^^44^558^6
 ;;^UTILITY(U,$J,358.3,9866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9866,1,3,0)
 ;;=3^Anterior Synechiae
 ;;^UTILITY(U,$J,358.3,9866,1,4,0)
 ;;=4^364.72
 ;;^UTILITY(U,$J,358.3,9866,2)
 ;;=Anterior Synechiae^265517
 ;;^UTILITY(U,$J,358.3,9867,0)
 ;;=364.71^^44^558^102
 ;;^UTILITY(U,$J,358.3,9867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9867,1,3,0)
 ;;=3^Posterior Synechiae
 ;;^UTILITY(U,$J,358.3,9867,1,4,0)
 ;;=4^364.71
 ;;^UTILITY(U,$J,358.3,9867,2)
 ;;=Posterior Synechiae^265519
 ;;^UTILITY(U,$J,358.3,9868,0)
 ;;=364.00^^44^558^57
 ;;^UTILITY(U,$J,358.3,9868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9868,1,3,0)
 ;;=3^Iridocyclitis,Acute/Subacute,Unspec
 ;;^UTILITY(U,$J,358.3,9868,1,4,0)
 ;;=4^364.00
 ;;^UTILITY(U,$J,358.3,9868,2)
 ;;=Iridocyclitis, Acute^268703
 ;;^UTILITY(U,$J,358.3,9869,0)
 ;;=379.40^^44^558^106
 ;;^UTILITY(U,$J,358.3,9869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9869,1,3,0)
 ;;=3^Pupil, Abnormal function
 ;;^UTILITY(U,$J,358.3,9869,1,4,0)
 ;;=4^379.40
 ;;^UTILITY(U,$J,358.3,9869,2)
 ;;=Pupil, Abnormal function^101288
 ;;^UTILITY(U,$J,358.3,9870,0)
 ;;=190.0^^44^558^84
 ;;^UTILITY(U,$J,358.3,9870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9870,1,3,0)
 ;;=3^Malig Neopl of Eyeball,Iris
 ;;^UTILITY(U,$J,358.3,9870,1,4,0)
 ;;=4^190.0
 ;;^UTILITY(U,$J,358.3,9870,2)
 ;;=Malig Neopl of Iris^267271
 ;;^UTILITY(U,$J,358.3,9871,0)
 ;;=190.3^^44^558^83
 ;;^UTILITY(U,$J,358.3,9871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9871,1,3,0)
 ;;=3^Malig Neopl Conjunctiva
 ;;^UTILITY(U,$J,358.3,9871,1,4,0)
 ;;=4^190.3
 ;;^UTILITY(U,$J,358.3,9871,2)
 ;;=Malig Neopl Conjunctiva^267274
 ;;^UTILITY(U,$J,358.3,9872,0)
 ;;=364.41^^44^558^50
 ;;^UTILITY(U,$J,358.3,9872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9872,1,3,0)
 ;;=3^Hyphema
 ;;^UTILITY(U,$J,358.3,9872,1,4,0)
 ;;=4^364.41
 ;;
 ;;$END ROU IBDEI0KT
